New Drug Approvals Archive
New Drug Approvals: April 2005
| April 7 | Fosamax Plus D (alendronate and cholecalciferol) Tablets Date of Approval: April 7, 2005 Company: Merck & Co., Inc. Treatment for Osteoporosis Fosamax Plus D is a single once-weekly tablet containing the bisphosphonate drug alendronate, and seven days’ worth of vitamin D, an essential nutrient required for calcium absorption. Fosamax Plus D is used to reduce the risk of hip and spinal fractures in postmenopausal women with osteoporosis, and to increase bone mass in men with osteoporosis. Fosamax Plus D Merck & Co., Inc. - Treatment for Osteoporosis |
| April 8 | Retisert () Intravitreal Implant Company: Bausch & Lomb Treatment for Chronic Non-Infectious Uveitis Retisert Bausch & Lomb - Treatment for Chronic Non-Infectious Uveitis |
| April 28 | Byetta (exenatide) Injection Date of Approval: April 28, 2005 Company: Amylin Pharmaceuticals / Eli Lilly & Co. Treatment for Diabetes Mellitus Type II Byetta is an incretin mimetic formulated for self-administration as a fixed dose, subcutaneous injection given prior to the morning and evening meals. Byetta is indicated as as adjunctive therapy to improve blood sugar control in patients with type 2 diabetes who have not achieved adequate control on metformin and/or a sulfonylurea, two common oral diabetes medications. Byetta Amylin Pharmaceuticals / Eli Lilly & Co. - Treatment for Type 2 Diabetes |
New Drug Approvals Archive
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Oct | Dec




